isoxazoles has been researched along with mk 0663 in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (54.17) | 29.6817 |
| 2010's | 10 (41.67) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Ouellet, M; Percival, MD; Riendeau, D | 1 |
| Hardy, KJ; McMurray, RW | 1 |
| Frölich, JC; Stichtenoth, DO | 1 |
| Capone, ML; Patrignani, P; Ricciotti, E; Sciulli, MG; Tacconelli, S | 1 |
| Cryer, B | 1 |
| Chan, VS | 1 |
| Benoit, V; de Leval, X; Dogné, JM; Frederich, M; Julémont, F; Pirotte, B | 1 |
| Brune, K; Hinz, B; Lambrecht, C; Werner, D; Werner, U | 1 |
| Hochberg, MC | 1 |
| Mullangi, R; Pavan Kumar, VV; Ramani, AV; Srinivas, NR; Vinu, MC | 1 |
| Bhatia, S; Seedher, N | 1 |
| Tabrizchi, R | 1 |
| Ashcroft, DM; Chen, LC | 1 |
| Berens, N; Bröcker, EB; Seitz, CS; Trautmann, A | 1 |
| Bhushan, A; Kaur, P; Mir, R; Sharma, S; Singh, N; Singh, TP; Sinha, M; Srinivasan, A; Vikram, G | 1 |
| Elliott, WJ | 1 |
| Bansal, AK; Bansal, SS; Kaushal, AM | 1 |
| Honjo, H; Iwamoto, K; Uwai, Y | 1 |
| Dahl, V; Raeder, JC; Spreng, UJ; Waage, M | 1 |
| Dávila, I; González, A; Laffond, E; Moreno, E; Muñoz-Bellido, F; Ponce, V | 1 |
| Hu, RW; Li, HY; Li, JS; Miao, XP; Ouyang, Q; Zhang, Y | 1 |
| Hansen, SH; Skonberg, C; Syed, M | 1 |
| Katchamart, W; Suwanawiboon, B; Tantayakom, P; Teerawattananon, C | 1 |
| Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K | 1 |
11 review(s) available for isoxazoles and mk 0663
| Article | Year |
|---|---|
Cox-2 inhibitors: today and tomorrow.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Etoricoxib; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Research; Sulfonamides; Sulfones | 2002 |
The second generation of COX-2 inhibitors: what advantages do the newest offer?
Topics: Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Interactions; Etoricoxib; Humans; Isoenzymes; Isoxazoles; Membrane Proteins; Organic Chemicals; Prostaglandin-Endoperoxide Synthases; Pyridines; Sulfonamides; Sulfones | 2003 |
The role of cyclooxygenase selective inhibitors in the gastrointestinal tract.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Digestive System; Etoricoxib; Humans; Isoxazoles; Pyridines; Sulfonamides; Sulfones; Ulcer | 2003 |
A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Female; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Pregnancy; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2004 |
First and second generations of COX-2 selective inhibitors.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2004 |
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Rheumatology; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones | 2007 |
Leg ulceration in rheumatoid arthritis--an underreported multicausal complication with considerable morbidity: analysis of thirty-six patients and review of the literature.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Arthritis, Rheumatoid; Etoricoxib; Female; Gram-Positive Bacterial Infections; Humans; Isoxazoles; Leflunomide; Leg; Leg Ulcer; Male; Methotrexate; Middle Aged; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Pyridines; Retrospective Studies; Risk Factors; Sulfones | 2010 |
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones | 2010 |
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Sulfones | 2014 |
Risk of perioperative bleeding related to highly selective cyclooxygenase-2 inhibitors: A systematic review and meta-analysis.
Topics: Blood Loss, Surgical; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Isoxazoles; Postoperative Hemorrhage; Pyridines; Risk Factors; Sulfones | 2017 |
1 trial(s) available for isoxazoles and mk 0663
| Article | Year |
|---|---|
Short stay and less pain after ambulatory anterior cruciate ligament (ACL) repair: COX-2 inhibitor versus glucocorticoid versus both combined.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Analysis of Variance; Anterior Cruciate Ligament Reconstruction; Blood Pressure; Cyclooxygenase 2 Inhibitors; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Etoricoxib; Female; Glucocorticoids; Humans; Injections, Intravenous; Isoxazoles; Length of Stay; Male; Middle Aged; Pain Measurement; Pain, Postoperative; Postoperative Nausea and Vomiting; Pyridines; Sample Size; Sulfones; Young Adult | 2012 |
12 other study(ies) available for isoxazoles and mk 0663
| Article | Year |
|---|---|
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.
Topics: Acetylation; Animals; Aspirin; Blood Platelets; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Ibuprofen; In Vitro Techniques; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sheep; Sulfonamides; Sulfones | 2001 |
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity.
Topics: Adult; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Female; Humans; In Vitro Techniques; Isoenzymes; Isoxazoles; Italy; Lactones; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyridines; Sulfonamides; Sulfones | 2002 |
A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma.
Topics: Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Isoxazoles; Male; Mass Spectrometry; Pyridines; Sensitivity and Specificity; Sulfonamides; Sulfones | 2005 |
Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection.
Topics: Animals; Celecoxib; Chromatography, High Pressure Liquid; Etoricoxib; Humans; Isoxazoles; Ketoprofen; Male; Pyrazoles; Pyridines; Rats; Rats, Wistar; Reproducibility of Results; Salicylic Acid; Spectrophotometry, Ultraviolet; Sulfonamides; Sulfones | 2006 |
Interaction of non-steroidal anti-inflammatory drugs, etoricoxib and parecoxib sodium, with human serum albumin studied by fluorescence spectroscopy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Drug Interactions; Etoricoxib; Humans; Isoxazoles; Pyridines; Serum Albumin; Spectrometry, Fluorescence; Sulfones; Thermodynamics | 2006 |
Coxibs: can this class of drugs survive?
Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Evidence-Based Medicine; Half-Life; Humans; Isoxazoles; Lactones; Patient Selection; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2005 |
Structural and binding studies of C-terminal half (C-lobe) of lactoferrin protein with COX-2-specific non-steroidal anti-inflammatory drugs (NSAIDs).
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Cattle; Crystallography, X-Ray; Cyclooxygenase 2 Inhibitors; Etoricoxib; In Vitro Techniques; Isoxazoles; Lactoferrin; Models, Molecular; Peptide Fragments; Protein Binding; Protein Conformation; Pyridines; Sulfonamides; Sulfones | 2010 |
Enthalpy relaxation studies of two structurally related amorphous drugs and their binary dispersions.
Topics: Calorimetry, Differential Scanning; Cyclooxygenase 2 Inhibitors; Drug Stability; Drug Storage; Etoricoxib; Excipients; Humidity; Hydrogen Bonding; Isoxazoles; Povidone; Pyridines; Sulfonamides; Sulfones; Thermodynamics; Transition Temperature | 2010 |
Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3.
Topics: Animals; Binding, Competitive; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Estrone; Etoricoxib; Humans; Inhibitory Concentration 50; Isoxazoles; Kinetics; Lactones; Methotrexate; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pyrazoles; Pyridines; RNA, Complementary; Sulfonamides; Sulfones; Xenopus laevis | 2010 |
Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib.
Topics: Aged; Arm; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Eruptions; Etoricoxib; Female; Humans; Isoxazoles; Leg Dermatoses; Low Back Pain; Patch Tests; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2012 |
Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria.
Topics: Adenosine Triphosphate; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Isoxazoles; Lactones; Male; Mitochondria, Liver; Oxidative Phosphorylation; Pyridines; Rats, Sprague-Dawley; Sulfonamides; Sulfones | 2016 |
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Etoricoxib; Female; Glioblastoma; Humans; Isoxazoles; Lactones; Male; Methylation; Middle Aged; Neoplasm Proteins; Pyrazoles; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Sulfones; Temozolomide; Tumor Suppressor Proteins; Wnt Signaling Pathway | 2021 |